Antibody response to influenza immunization in coronary artery disease patients: A controlled trial

Maryam Keshtkar-Jahromi; Hossein Vakili; Mohammad Rahnavardi; Sharareh Gholamin; Seyed Mostafa Razavi; Ali Eskandari; Roxana Sadeghi; Hossein Vatan-Pour; Marzieh Keshtkar-Jahromi; Babak Haghighat; Mohammad Ghaffaripour; Talat Mokhtari-Azad

doi:10.1016/j.vaccine.2009.09.108

Antibody response to influenza immunization in coronary artery disease patients: A controlled trial

Maryam Keshtkar-Jahromi, Hossein Vakili, Mohammad Rahnavardi, Sharareh Gholamin, Seyed Mostafa Razavi, Ali Eskandari, Roxana Sadeghi, Hossein Vatan-Pour, Marzieh Keshtkar-Jahromi, Babak Haghighat, Mohammad Ghaffaripour, Talat Mokhtari-Azad

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Safety of and humoral immune response to the anti-influenza vaccine in coronary artery disease (CAD) patients were evaluated. The trivalent vaccine was administered to 137 eligible CAD patients and 67 age- and sex-matched healthy individuals. Antibody (Ab) titers were measured before and 1 month after vaccination. CAD and HC groups were not significantly different in serologic response and magnitude of change in antibody titers against each of the vaccine antigens. In multivariate analyses, regular exercise and using multivitamin supplements were independently associated with better antibody response among CAD patients. There were no major cardiac or general adverse effects. Influenza vaccine was found safe in CAD patients and antibody responses were similar to HCs.

Original language	English (US)
Pages (from-to)	110-113
Number of pages	4
Journal	Vaccine
Volume	28
Issue number	1
DOIs	https://doi.org/10.1016/j.vaccine.2009.09.108
State	Published - Dec 10 2009
Externally published	Yes

Keywords

Antibody
Coronary artery disease
Influenza vaccine
Serologic response

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/j.vaccine.2009.09.108

Cite this

Keshtkar-Jahromi, M., Vakili, H., Rahnavardi, M., Gholamin, S., Razavi, S. M., Eskandari, A., Sadeghi, R., Vatan-Pour, H., Keshtkar-Jahromi, M., Haghighat, B., Ghaffaripour, M., & Mokhtari-Azad, T. (2009). Antibody response to influenza immunization in coronary artery disease patients: A controlled trial. Vaccine, 28(1), 110-113. https://doi.org/10.1016/j.vaccine.2009.09.108

Keshtkar-Jahromi, M, Vakili, H, Rahnavardi, M, Gholamin, S, Razavi, SM, Eskandari, A, Sadeghi, R, Vatan-Pour, H, Keshtkar-Jahromi, M, Haghighat, B, Ghaffaripour, M & Mokhtari-Azad, T 2009, 'Antibody response to influenza immunization in coronary artery disease patients: A controlled trial', Vaccine, vol. 28, no. 1, pp. 110-113. https://doi.org/10.1016/j.vaccine.2009.09.108

@article{c99ebf509d054c06a7a3dd8add71d08a,

title = "Antibody response to influenza immunization in coronary artery disease patients: A controlled trial",

abstract = "Safety of and humoral immune response to the anti-influenza vaccine in coronary artery disease (CAD) patients were evaluated. The trivalent vaccine was administered to 137 eligible CAD patients and 67 age- and sex-matched healthy individuals. Antibody (Ab) titers were measured before and 1 month after vaccination. CAD and HC groups were not significantly different in serologic response and magnitude of change in antibody titers against each of the vaccine antigens. In multivariate analyses, regular exercise and using multivitamin supplements were independently associated with better antibody response among CAD patients. There were no major cardiac or general adverse effects. Influenza vaccine was found safe in CAD patients and antibody responses were similar to HCs.",

keywords = "Antibody, Coronary artery disease, Influenza vaccine, Serologic response",

author = "Maryam Keshtkar-Jahromi and Hossein Vakili and Mohammad Rahnavardi and Sharareh Gholamin and Razavi, {Seyed Mostafa} and Ali Eskandari and Roxana Sadeghi and Hossein Vatan-Pour and Marzieh Keshtkar-Jahromi and Babak Haghighat and Mohammad Ghaffaripour and Talat Mokhtari-Azad",

year = "2009",

month = dec,

day = "10",

doi = "10.1016/j.vaccine.2009.09.108",

language = "English (US)",

volume = "28",

pages = "110--113",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "1",

}

TY - JOUR

T1 - Antibody response to influenza immunization in coronary artery disease patients

T2 - A controlled trial

AU - Keshtkar-Jahromi, Maryam

AU - Vakili, Hossein

AU - Rahnavardi, Mohammad

AU - Gholamin, Sharareh

AU - Razavi, Seyed Mostafa

AU - Eskandari, Ali

AU - Sadeghi, Roxana

AU - Vatan-Pour, Hossein

AU - Keshtkar-Jahromi, Marzieh

AU - Haghighat, Babak

AU - Ghaffaripour, Mohammad

AU - Mokhtari-Azad, Talat

PY - 2009/12/10

Y1 - 2009/12/10

N2 - Safety of and humoral immune response to the anti-influenza vaccine in coronary artery disease (CAD) patients were evaluated. The trivalent vaccine was administered to 137 eligible CAD patients and 67 age- and sex-matched healthy individuals. Antibody (Ab) titers were measured before and 1 month after vaccination. CAD and HC groups were not significantly different in serologic response and magnitude of change in antibody titers against each of the vaccine antigens. In multivariate analyses, regular exercise and using multivitamin supplements were independently associated with better antibody response among CAD patients. There were no major cardiac or general adverse effects. Influenza vaccine was found safe in CAD patients and antibody responses were similar to HCs.

AB - Safety of and humoral immune response to the anti-influenza vaccine in coronary artery disease (CAD) patients were evaluated. The trivalent vaccine was administered to 137 eligible CAD patients and 67 age- and sex-matched healthy individuals. Antibody (Ab) titers were measured before and 1 month after vaccination. CAD and HC groups were not significantly different in serologic response and magnitude of change in antibody titers against each of the vaccine antigens. In multivariate analyses, regular exercise and using multivitamin supplements were independently associated with better antibody response among CAD patients. There were no major cardiac or general adverse effects. Influenza vaccine was found safe in CAD patients and antibody responses were similar to HCs.

KW - Antibody

KW - Coronary artery disease

KW - Influenza vaccine

KW - Serologic response

UR - http://www.scopus.com/inward/record.url?scp=70749157038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70749157038&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.09.108

DO - 10.1016/j.vaccine.2009.09.108

M3 - Article

C2 - 19819210

AN - SCOPUS:70749157038

SN - 0264-410X

VL - 28

SP - 110

EP - 113

JO - Vaccine

JF - Vaccine

IS - 1

ER -

Antibody response to influenza immunization in coronary artery disease patients: A controlled trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this